Senvest Management LLC raised its stake in Trinity Biotech PLC (NASDAQ:TRIB) by 25.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 892,488 shares of the company’s stock after purchasing an additional 178,666 shares during the period. Senvest Management LLC owned approximately 3.71% of Trinity Biotech worth $5,007,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. State Street Corp boosted its holdings in Trinity Biotech by 2.1% in the 2nd quarter. State Street Corp now owns 37,614 shares of the company’s stock valued at $225,000 after purchasing an additional 781 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Trinity Biotech by 21.1% during the 1st quarter. Renaissance Technologies LLC now owns 164,650 shares of the company’s stock worth $981,000 after acquiring an additional 28,700 shares during the period. Teton Advisors Inc. lifted its holdings in shares of Trinity Biotech by 0.3% during the 2nd quarter. Teton Advisors Inc. now owns 231,730 shares of the company’s stock worth $1,390,000 after acquiring an additional 800 shares during the period. Adirondack Research & Management Inc. lifted its holdings in shares of Trinity Biotech by 4.1% during the 3rd quarter. Adirondack Research & Management Inc. now owns 334,175 shares of the company’s stock worth $1,875,000 after acquiring an additional 13,191 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Trinity Biotech by 19.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 457,577 shares of the company’s stock worth $2,745,000 after acquiring an additional 74,374 shares during the period. 60.47% of the stock is owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research downgraded shares of Trinity Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 30th.

Trinity Biotech PLC (NASDAQ:TRIB) opened at $4.90 on Monday. The company has a market cap of $117.80, a PE ratio of 81.67 and a beta of 1.41. Trinity Biotech PLC has a 1-year low of $4.22 and a 1-year high of $7.27. The company has a current ratio of 5.16, a quick ratio of 3.77 and a debt-to-equity ratio of 0.90.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $25.60 million during the quarter, compared to the consensus estimate of $25.52 million. Trinity Biotech had a negative net margin of 100.00% and a positive return on equity of 5.87%. research analysts anticipate that Trinity Biotech PLC will post 0.06 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/senvest-management-llc-raises-holdings-in-trinity-biotech-plc-trib/1742534.html.

About Trinity Biotech

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Want to see what other hedge funds are holding TRIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trinity Biotech PLC (NASDAQ:TRIB).

Institutional Ownership by Quarter for Trinity Biotech (NASDAQ:TRIB)

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.